InvestorsHub Logo
Followers 24
Posts 3015
Boards Moderated 0
Alias Born 01/18/2009

Re: None

Thursday, 02/26/2009 8:54:11 AM

Thursday, February 26, 2009 8:54:11 AM

Post# of 23113
ANPI receives approval for Quill(TM) SRS PDO, MONODERM(TM) ...

http://ih.advfn.com/p.php?pid=nmona&cb=1235656119&article=36423675&symbol=N^ANPI

Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines for sale in Canada

VANCOUVER, Feb. 26 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received 510(k) clearance to begin marketing the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM) and Nylon product lines in Canada.

"With the approval of the PDO, MONODERM(TM) and Nylon product lines in Canada, we can further extend the global reach of this next-generation suture product beyond the U.S. and Europe," said Dr. William Hunter, President and CEO of Angiotech.

Quill(TM) SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures while Quill(TM) SRS MONODERM(TM) is made from a rapidly resorbing polymer and intended primarily for superficial wound closure applications and soft tissue approximation where use of an absorbable suture is appropriate. The monofilament Quill(TM) SRS Nylon is a polyamide suture indicated for use in soft tissue approximation excluding closure of the epidermis.

Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines have both been previously approved for sale in the U.S. and Europe.

About the Quill(TM) Self-Retaining System (SRS)

Quill(TM) SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill(TM) SRS distribute tension across the wound and eliminate the need for knots.

...



http://shortsqueeze.com/?symbol=anpi&submit=Short+Quote%99

Angiotech Pharmaceuticals Inc. $ 0.28
ANPI
Short Interest (Shares Short) 363,700
Days To Cover (Short Interest Ratio) 2.0
Short Percent of Float %
Short Interest - Prior 834,000
Short % Increase / Decrease -56.39 %
Short Squeeze Ranking™
% From 52-Wk High ($ 3.49 ) -1141.99 %
% From 52-Wk Low ($ 0.10 ) 64.41 %
% From 200-Day MA ($ 0.61 ) -117.08 %
% From 50-Day MA ($ 0.37 ) -31.67 %
Price % Change (52-Week) -91.10 %
Shares Float
Total Shares Outstanding 85,121,983
% Owned by Insiders %
% Owned by Institutions %
Market Cap. $ 23,919,277
Trading Volume - Today 131,788
Trading Volume - Average 178,600
Trading Volume - Today vs. Average 73.79 %
Earnings Per Share -8.15
PE Ratio
Record Date 2009-FebB

posts are IMHO // either news - with LINK

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.